This inventor holds 1 USPTO granted patent. Top assignee: Seoul National University. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Hyun-Ji Jang: Innovator in Lung Disease Prevention
Introduction
Hyun-Ji Jang is a notable inventor based in Yeongju, South Korea. He has made significant contributions to the field of medicine, particularly in the prevention of lung diseases. His innovative approach utilizes existing antihypertensive drugs to combat serious health issues related to smoking and other risk factors.
Latest Patents
Hyun-Ji Jang holds a patent for a method aimed at preventing lung diseases in both smokers and non-smokers. The patent, titled "Method for preventing lung diseases in smokers and non-smokers using antihypertensive drug," describes a pharmaceutical composition that employs an antihypertensive drug as an active ingredient. This invention focuses on blocking growth factor signaling to inhibit the development of lung cancer and emphysema. The method presents a novel application of antihypertensive drugs, which are already in clinical use, thereby enhancing their clinical applicability and potentially reducing the costs and time associated with developing new drugs.
Career Highlights
Hyun-Ji Jang is affiliated with Seoul National University, where he continues to advance his research and innovations. His work is pivotal in bridging the gap between existing medications and their new applications in preventing lung diseases.
Collaborations
Hyun-Ji Jang collaborates with esteemed colleagues, including Ho-Young Reho Lee and Hye-Young Min. Their combined expertise contributes to the ongoing research and development of effective treatments for lung diseases.
Conclusion
Hyun-Ji Jang's innovative work in utilizing antihypertensive drugs for lung disease prevention showcases his commitment to improving public health. His contributions are expected to have a lasting impact on the medical field and the lives of many individuals at risk of lung diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
